GLENMARK PHARMA (GLENMARK) - Live BSE, NSE Stock Quotes - GLENMARK PHARMA Analysis Update - Equitymaster.com
X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2016 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA   (GLPH)

REFRESH
Live BSE Quotes Sep 23, 2016 (Close)
Price (Rs)945.25 Open (Rs) 934.95 High (Rs) 954.00 Low (Rs) 932.15
% Change1.67 Volume 180,074 Value (Rs) 170,319,456 52-Week H/L 1,074.90 / 671.50
Live NSE Quotes Sep 23, 2016 (Close)
Price (Rs)945.75 Open (Rs) 935.00 High (Rs) 954.00 Low (Rs) 932.00
% Change1.69 Volume 1,216,371 Value (Rs) 1,149,130,196 52-Week H/L 1,074.90 / 671.10
Valuation
EPS (Rs)* 28.33 P/E Ratio (x) 33.36 Market Cap (Rs m) 256,427.42 P/BV (x) 6.00
  *Trailing 12 months earnings, excluding extraordinary / exceptional items. BSE Sensex | CNX Nifty

Charts
GLENMARK PHARMA Stock Price Chart (Rs) - 1 Year
Loading...
 
Peer Group:
Quote & Graph
     
 S&P BSE SENSEX 
PERIOD
Advanced Charts new

Related Views On News

Glenmark: Other Income Boosts Profit Growth (Quarterly Results Update - Detailed)

Sep 6, 2016

Glenmark has announced its 1QFY17 results. The company has reported 15.8% YoY growth in net sales and 24% YoY increase in net profits. Here is our analysis of the results.

Glenmark: Margins under Pressure (Quarterly Results Update - Detailed)

Jun 22, 2016

Glenmark has announced its 4QFY16 results. The company has reported 30.5% YoY growth in sales and 1255.8% YoY increase in net profits. Here is our analysis of the results.

Glenmark: Emerging markets disappoint (Quarterly Results Update - Detailed)

Feb 5, 2016

Glenmark has announced its 3QFY16 results. The company has reported 4.5% YoY growth in sales and 48.3% YoY increase in net profits. Here is our analysis of the results.

Biocon: Lower R&D Expenses Help Margin Expansion (Quarterly Results Update - Detailed)

Sep 19, 2016

Biocon has announced its 1QFY17. The company has reported 21.1% YoY growth in total income and 34.6% YoY increase in net profits. Here is our analysis of the results.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

More Views on News

Most Popular

Jaitley's New Real Estate Pipe Dream: Where Rents Equal EMIs(Vivek Kaul's Diary)

Sep 13, 2016

The finance minister at a recent conference got nostalgic about the Vajpayee era when rents were fairly close to EMIs.

Here's One More Reason to Believe in Sensex 40,000(The 5 Minute Wrapup)

Sep 14, 2016

Strong faith of foreign promoters in the Indian economy cements our long-term view on the Sensex.

Which Tata Company has done the best under Cyrus Mistry?(Chart Of The Day)

Sep 15, 2016

Voltas and Tata Communications top performers under Cyrus Mistry.

What is Open Interest?(Daily Profit Hunter)

Sep 14, 2016

Apurva Sheth talks about the sixth primary data point in futures and options market - Open Interest.

Should You Worry About How Much Your Fund Manager Earns?(Outside View)

Sep 19, 2016

PersonalFN explains why instead of focusing merely on how much your fund manager earns, a holistic assessment is imperative to select mutual funds prudently for your investment portfolio.

More

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

Detailed Financial Information With Charts

COMPARE GLENMARK PHARMA WITH

MARKET STATS